Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service BPH procedures cases in New Hampshire: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 12 | 837 | 21% |
| 2020 | 8 | 821 | 25% |
| 2021 | 13 | 1,070 | 29% |
| 2022 | 9 | 998 | 33% |
| 2023 | 13 | 1,089 | 37% |
| 2024 | 11 | 730 | 39% |
| 2025 from claims | – | 695 562–816 | 40% |
| 2026 forecast | – | 772 605–969 | 35% |
| 2027 forecast | – | 797 591–1,054 | 34% |
| 2028 forecast | – | 823 583–1,136 | 34% |
| 2029 forecast | – | 850 578–1,219 | 33% |
| 2030 forecast | – | 878 575–1,303 | 33% |
TURP, laser enucleation and vaporization, UroLift, Rezum. Professional codes (what the surgeon bills): CPT 52601, 52648, 52649, 52441, 52442, 53854, 55874.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 97% of the cases CMS names in New Hampshire; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 75% hospital outpatient, 25% office. The share outside the hospital has moved −11 pts since 2019.
| Forecast, Medicare FFS | Hospital outpatient | Office |
|---|---|---|
| 2026 · ~770 | ~590 | ~180 |
| 2027 · ~800 | ~620 | ~180 |
| 2028 · ~820 | ~640 | ~180 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 22% (25% in 2025), hospital outpatient about 78% (75% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 98 | 8,386−6.8%/yr | −6.8%/yr | 4.6 | 43% | 8,420 in 2030+0.1%/yr |
| New Jersey | 53 | 6,600−1.2%/yr | −1.2%/yr | 6.3 | 53% | 5,800 in 2030−2.1%/yr |
| Pennsylvania | 78 | 5,698−7.3%/yr | −7.3%/yr | 4.2 | 31% | 4,890 in 2030−2.5%/yr |
| Massachusetts | 46 | 2,725−3.2%/yr | −3.2%/yr | 2.9 | 13% | 2,910 in 2030+1.1%/yr |
| Connecticut | 20 | 1,316+0.2%/yr | +0.2%/yr | 3.9 | 19% | 1,290 in 2030−0.3%/yr |
| Maine | 6 | 406−1.3%/yr | −1.3%/yr | 2.6 | 0% | 340 in 2030−2.8%/yr |
| Rhode Island | 5 | 342+2.1%/yr | +2.1%/yr | 3.7 | 20% | 270 in 2030−3.7%/yr |
| Vermont | 3 | 213−6.2%/yr | −6.2%/yr | 1.9 | 0% | 320 in 2030+7.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 22 | 921−1.3%/yr | −1.3%/yr | 4.10.7× | 2% | 1,150 in 2030+3.8%/yr |
| Hysterectomy, hysteroscopy & ablation | 3 | 531−0.4%/yr | −0.4%/yr | 2.50.7× | 6% | 910 in 2030+9.3%/yr |
| Incontinence, prolapse & sacral neuromodulation | 5 | 344−2.3%/yr | −2.3%/yr | 1.50.8× | 0% | 460 in 2030+4.9%/yr |
| Prostatectomy & nephrectomy | 5 | 194−3.3%/yr | −3.3%/yr | 0.90.8× | 0% | 300 in 2030+7.6%/yr |
BPH procedures in every state, and its device makers · Every procedure market in New Hampshire · Every state · Compare with New York
Boston Scientific leads with 90% of company spending on these surgeons in 2025, +58 pts on 2024.
In 2025, 4 companies reported engagement with New Hampshire’s surgeons worth $5,882 in consulting, speaking, meals and travel tied to these products, about $535 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.